Authors
Latest:
Reviewing the Phase 2 OVERTURE Results of Gamma Sensory Stimulation Device: Brent VaughanThe chief executive officer of Cognito Therapeutics detailed clinical findings from the open-label extension of the phase 2 OVERTURE study presented at the recent Clinical Trials on Alzheimer’s Disease conference. [WATCH TIME: 4 minutes]
Latest:
Future Implications, Outlook of New CDC Developmental Milestone Guidelines: Paul Lipkin, MDThe director of medical outpatient services at the Kennedy Krieger Institute discussed the long-term effects of the updated developmental milestone guidelines and the need to judge children based on the 75th percentile. [WATCH TIME: 7 minutes]
Latest:
Changes in Vocation as Early Signs for Alzheimer Disease, Cognitive Issues: Alvaro Pascual-Leone, MD, PhDThe chief medical officer and cofounder of Linus Health discussed how changes in voice may help serve as early indicators for late-life cognitive deficits. [WATCH TIME: 3 minutes]
Latest:
A Call for Urgent Action to Redefine Stroke Protocols: Stephan A. Mayer, MD, FCCM, FNCSThe director of neurocritical care and emergency neurology services at Westchester Medical Center Health System talked about a recently published paper that highlighted the need to address the disparity in quality metrics for stroke care, especially for intracerebral hemorrhage. [WATCH TIME: 4 minutes]
Latest:
Next Steps in Tackling CDKL5 Deficiency Disorder Following First Approval: Elia Pestana-Knight, MDThe pediatric epileptologist from Cleveland Clinic provided commentary on the changes needed to improve research and drug development in CDKL5 deficiency disorder, as well as the organizations committed to advancing the state of care. [WATCH TIME: 3 minutes]
Latest:
Using the Cionic Neural Sleeve to Alleviate Gait Dysfunction in Multiple Sclerosis: Douglas A. Wajda, PhDThe assistant professor of neurology at Cleveland State University provided perspective on an early-stage study assessing the impacts of a functional electrical stimulation approach to treat gait problems in multiple sclerosis. [WATCH TIME: 4 minutes]
Latest:
Applying the Innovation Biodesign Framework to Promote Equity and Green Activity in Dementia CareLassell et al present a use case demonstrating the process of moving an unmet need to the “solution space” of the Innovation Biodesign Framework for addressing a healthcare challenge in a specific at-risk population: Alzheimer disease and AD-related dementias.
Latest:
Targeting Neuroinflammation in Huntington Disease: Rajeev Kumar, MDThe medical director of the Rocky Mountain Movement Disorders Center talked about the motivations of the phase 2 study on ANX005 for Huntington disease at the 2023 AAN Annual Meeting. [WATCH TIME: 3 minutes]
Latest:
Expanding Neuropalliative Care to New Disease States: Benzi Kluger, MD, MSThe president of the International Neuropalliative Care Society detailed potential disease states that could benefit from neuropalliative care as well as the importance of the patient community in expanding this type of approach. [WATCH TIME: 4 minutes]
Latest:
Effectiveness and Promise of Glatiramer Acetate Depot in Progressive Multiple Sclerosis: Ehud MaromThe president and chief executive officer of Mapi Pharma discussed the positive phase 2 findings of a new formulation of glatiramer acetate to treat progressive forms of MS, as well as the long-term plans for the drug. [WATCH TIME: 5 minutes]
Latest:
Not Your Grandmother’s Dopamine: PMD Alliance Releases On-Demand CME Topics in Advanced Therapeutics in Movement-Related DisordersThe PMD Alliance has developed a group of 6 on-demand CME events and live panel discussions, in partnership with MedStar Georgetown University Hospital, taking place on October 23-24, 2021, developed and presented by Yasar Torres-Yaghi, MD , and Fernando Pagan, MD.
Latest:
Capabilities of Deep Brain Stimulation to Modulate Late-Stage Neuroplasticity: Kenneth Baker, PhDThe associate staff member in the department of neurology at Cleveland Clinic discussed the major take-home points and post-hoc findings from a positive study of deep brain stimulation in poststroke patients. [WATCH TIME: 3 minutes]
Latest:
Unmasking Long COVID Through Understanding Prevalence and DiagnosisIn our latest roundtable series, experts discussed Long COVID prevalence, underreporting, accurate diagnosis, and emphasized that Long COVID serves as an umbrella term.
Latest:
FDA to Add Warning Related to Guillain-Barré Syndrome on Johnson & Johnson VaccineSince vaccine administration, the CDC has announced 100 preliminary cases of Guillain-Barré syndrome.
Latest:
A Team Approach to Asleep Deep Brain StimulationHenry Ford Health System’s investment in advanced DBS technology and its commitment to multidisciplinary care has helped them become a leading treatment center for Parkinson disease and related movement disorders.
Latest:
Assessing the Impact of Gut Microbiota on Neuroprotection in Alzheimer Disease: Yannick J. Wadop Ngouongo, PhDThe postdoctoral researcher at The University of Texas Health Science Center at San Antonio talked the gut microbiome and neurological disorders, focusing on the potential role of gut microbiota imbalance in the pathogenesis of conditions like Alzheimer disease. [WATCH TIME: 5 minutes]
Latest:
AUPN Leadership Minute Episode 38: Visa Issues for FacultyEpisode 38 of the AUPN Leadership Minute features Muhammad "Mud" Alvi, MD, of West Virginia University Robert C. Byrd Health; and David B. Watson, MD, of West Virginia University Robert C. Byrd Health. [WATCH TIME: 5 minutes]
Latest:
Effects of Long-term CPAP Therapy in Multiple Sclerosis: Daria Trojan, MD, MScThe associate professor in the department of neurology and neurosurgery at McGill University discussed results from a study on the long-term use of continuous positive airway pressure treatment among patients with multiple sclerosis and sleep apnea presented at MSMilan 2023. [WATCH TIME: 5 minutes]
Latest:
Promising Disease-Modifying Therapies in Parkinson DiseaseDespite years of use of gold-standard therapy levodopa, therapeutic development in Parkinson disease has advanced rapidly and expanded to numerous novel pathways and targets.
Latest:
Key Considerations in Treatment of Spinal Muscular Atrophy / Considerações essenciais para o tratamento da atrofia muscular espinhalThe expert panel shares clinical pearls for treatment and management of Spinal Muscular Atrophy. O painel de especialistas compartilha recomendações valiosas para o tratamento e manejo da atrofia muscular espinhal.
Latest:
Aducanumab’s Implications for Future Clinical Trials: Pierre N. Tariot, MDIn addition to his work study pimavanserin in treating dementia-related psychosis, the director of the Banner Alzheimer’s Institute commented on the potential for aducanumab in Alzheimer disease.
Latest:
Challenges With Addressing Neurodegeneration in Poststroke Patients: Stephen FromThe chief executive officer of Aruna Bio discussed the reasons for the failure of neuroprotective agents in ischemic stroke trials and why AB126 has potential to restore neurodegeneration in such affected patients. [WATCH TIME: 3 minutes]
Latest:
Advice for Clinicians Treating SpasticityExperts on spasticity provide advice for practicing clinicians to optimize patient outcomes.
Latest:
Role of Cholinergic Transcripts in Sex-Specific Declines of Alzheimer Disease: Hermona Seroq, PhDThe professor of molecular neuroscience at the Edmond and Lily Safra Center for Brain Sciences discussed the premise behind a study of RNA-sequencing data to better understand the reasons why females suffer accelerated dementia. [WATCH TIME: 9 minutes]
Latest:
Trends in Movement Disorder Research: Ihtsham ul Haq, MD, FAANThe chief of Movement Disorders Division at the University of Miami Miller School of Medicine discussed some of the recent focused efforts to uncover more about Parkinson disease and what is on the horizon.
Latest:
Jonathan Graff-Radford, MD: Blood Tests as a Diagnostic Innovation in Alzheimer DiseaseThe neurologist at Mayo Clinic detailed promising diagnostic tools, including the revelation of blood tests in patients with Alzheimer disease.
Latest:
Challenges and Opportunities Bringing Lecanemab to Neurology Community ClinicsA group of experts from The Neuron Clinic shared their experience developing a novel inclusive clinical program to treat patients with early Alzheimer disease using lecanemab.
Latest:
CNS Demyelination and Autoimmune Neurology: Spencer Hutto, MDThe fellow of autoimmune neurology at Massachusetts General Hospital also discussed concerns of associations between multiple sclerosis and COVID-19.
Latest:
Elias Kouchakji, MD: Investigating Pamrevlumab for DMD in Phase 3 LELANTOS StudyThe senior vice president of clinical development, drug safety, and pharmacovigilance at FibroGen provides details of the phase 3 LELANTOS trial of pamrevlumab in Duchenne muscular dystrophy.
